調(diào)肝理脾法治療腹瀉型腸易激綜合征癥狀療效觀察.pdf

《調(diào)肝理脾法治療腹瀉型腸易激綜合征癥狀療效觀察.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫(kù)。

1、世界中醫(yī)藥2015年5月第10卷第5期調(diào)肝理脾法治療腹瀉型腸易激綜合征癥狀療效觀察汪正芳張聲生(首都醫(yī)科大學(xué)附屬北京中醫(yī)醫(yī)院消化中心，北京，100010)摘要目的：觀察調(diào)肝理脾法治療腹瀉型腸易激綜合征(IBS—D)的臨床療效。方法：97例IBS—D患者隨機(jī)分為調(diào)肝理脾中藥組和匹維溴銨西藥紐，分別給予調(diào)肝理脾方及匹維溴銨治療。療程均為4周，療程結(jié)束后隨訪3個(gè)月，觀察癥狀療效。結(jié)果：治療2周后、治療4周后、治療結(jié)束后第1個(gè)月及第3個(gè)月隨訪時(shí)，2組總癥狀積分改善明顯優(yōu)于治療前，差異有統(tǒng)計(jì)學(xué)意義(P<0．05)；治療4周后，2組

2、病例IBS癥狀積分減少值，調(diào)肝理脾組優(yōu)于匹維溴銨紐，差異有統(tǒng)計(jì)學(xué)意義(P

3、withDiarrhea(mS-D)byRegulatingLiverandSpleenWangZhengfang，ZhangShengsheng(Digestioncenter，BeijingTCMHospitalAffiliatedToCapitalMedicalUniversity，Beijing100010，China)AbstractObjective：Toobservetheclinicaleficacyofthemethodofregulatingliverandspleenontreatingirrita

4、blebowelsyn-dromeofdiarrheapattern．Methods：Atotalof97IBS—Dpatientswererandomlydividedintotwogroups．Onegroupreceivedtradi-tionalChinesemedicinetreatmentwhichhaseffectofregulatingliverandspleen；andtheothergroupreceivedpinaveriumbro—mide．Bothgroupsreceivedthetreatme

5、ntfor4weeks．Wefollowedupthepatientsfor3monthsaftertreatmenttoobservethesymptomsandthecurativeeffect．Results：Thesymptomsofbothgroupsshowedobviousimprovementthanbeforethetreatmentwhenitwasobservedafter2weeksand4weeksoftreatment。andlmonthand3monthsaftertreatment．The

6、rewerestatisticaldifferences(P<0．05)．After4weeksoftreatment，thesymptomreductionvalueofregulatingliverandspleengroupwasbetterthanthatofpinaveriumbromidegroupwithstatisticallysignificantdifference(P<0．05)；thetotaleffectivenessoftheregulatingliverandspleengroupwas92

7、．2％andpinaveriumbromidegroupwas69．6％．itindicatedthatregulatingliverandspleengroupwasbetterthanthepinaveriumbromidegroupandthedifferencewasstatisticallysignificant(P<0．05)．Intherespectofimpro—ringthemajorsymptomssuchasthenumberofdefecationandcharacterofstool，there

8、gulatingliverandspleengroupwassuperiorthanpinaveriumbromidegroup，andthedifferencewasstatisticallysignificant(P<0．05)．Conclusion：Theprescriptionofregn—latingliv